α-Naphthylamino-2-chlormethyl-4-thiazol | 21917-60-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: α-Naphthylamino-2-chlormethyl-4-thiazol
• 英文别名: (4-chloromethyl-thiazol-2-yl)-naphthalen-1-yl-amine；4-(chloromethyl)-N-naphthalen-1-yl-1,3-thiazol-2-amine
• CAS: 21917-60-2
• 化学式: C₁₄H₁₁ClN₂S
• 分子量: 274.774
• InChiKey: BDORUILOACDKQW-UHFFFAOYSA-N

物化性质

• 沸点：
  462.5±37.0 °C(Predicted)
• 密度：
  1.373±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  53.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  二异丁胺 、 α-Naphthylamino-2-chlormethyl-4-thiazol 在 碳酸氢钠 、 sodium iodide 作用下， 以 丙酮 为溶剂， 反应 2.0h， 生成 {4-[(Diisobutylamino)-methyl]-thiazol-2-yl}-naphthalen-1-yl-amine
  参考文献：
  名称：

  Optimization of 2-aminothiazole derivatives as CCR4 antagonists

  摘要：

  A series of 2-aminothiazole-derived antagonists of the CCR4 receptor has been synthesized and their affinity for the receptor evaluated using a [I-125]TARC (CCL17) displacement assay. Optimization of these compounds for potency and pharmacokinetic properties led to the discovery of potent, orally bioavailable antagonists. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.126
• 作为产物：
  描述：

  1-苯甲酰基-3-(1-萘基)硫脲 在 sodium hydroxide 作用下， 以 丙酮 为溶剂， 反应 0.17h， 生成 α-Naphthylamino-2-chlormethyl-4-thiazol
  参考文献：
  名称：

  Optimization of 2-aminothiazole derivatives as CCR4 antagonists

  摘要：

  A series of 2-aminothiazole-derived antagonists of the CCR4 receptor has been synthesized and their affinity for the receptor evaluated using a [I-125]TARC (CCL17) displacement assay. Optimization of these compounds for potency and pharmacokinetic properties led to the discovery of potent, orally bioavailable antagonists. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.126

文献信息

• CCR4 antagonists
  申请人：Amgen Inc.

  公开号：US07144903B2

  公开（公告）日：2006-12-05

  Compounds, compositions and methods are provided that are useful in the treatment of chemokine receptor-mediated conditions and diseases. In particular, the invention provides compounds which modulate CCR4 function or a CCR4-mediated response. The subject compounds and compositions are useful for the treatment or prevention of inflammatory conditions and diseases.

  本发明提供了在治疗趋化因子受体介导的疾病和症状方面有用的化合物、组合物和方法。特别地，本发明提供了调节CCR4功能或CCR4介导反应的化合物。这些化合物和组合物可用于治疗或预防炎症性疾病。
• Ccr4 antagonists
  申请人：Tularik Inc.

  公开号：US20030018022A1

  公开（公告）日：2003-01-23

  Compounds, compositions and methods are provided that are useful in the treatment of chemokine receptor-mediated conditions and diseases. In particular, the invention provides compounds which modulate CCR4 function or a CCR4-mediated response. The subject compounds and compositions are useful for the treatment or prevention of inflammatory conditions and diseases.

  本发明提供了可用于治疗趋化因子受体介导的病症和疾病的化合物、组合物和方法。特别是，本发明提供了调节 CCR4 功能或 CCR4 介导的反应的化合物。本发明的化合物和组合物可用于治疗或预防炎症和疾病。
• US7144903B2
  申请人：——

  公开号：US7144903B2

  公开（公告）日：2006-12-05
• US7262204B2
  申请人：——

  公开号：US7262204B2

  公开（公告）日：2007-08-28
• [EN] CCR4 ANTAGONISTS<br/>[FR] ANTAGONISTES DE CCR4
  申请人：TULARIK INC

  公开号：WO2002094264A1

  公开（公告）日：2002-11-28

  Compounds, compositions and methods are provided that are useful in the treatment of chemokine receptor-mediated conditions and diseases. In particular, the invention provides compounds which modulate CCR4 function or a CCR4-mediated response. The subject compounds and compositions are useful for the treatment or prevention of inflammatory conditions and diseases.